Canada - TSX:CRDL - CA14161Y2006 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to CRDL.CA. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-11-08 | Raymond James Capital | Downgrade | Market Perform |
| 2022-09-01 | Raymond James Capital | Downgrade | Market Perform |
| 2022-04-18 | Canaccord Capital | Reiterate | Buy |
| 2022-03-17 | Raymond James Capital | Downgrade | Market Perform |
| 2022-02-04 | Raymond James Financial | Initiate | Outperform |
| 2021-11-11 | RaymondJamesFinancial | Initiate | Outperform |
| 2021-08-25 | Raymond James Financial | Upgrade | Outperform |
| 2021-05-19 | ATB Catpital | Downgrade | Speculative Buy |
| 2021-05-19 | ATB Capital | Downgrade | |
| 2021-05-17 | Raymond James Financial | Upgrade | Outperform |
| 2021-04-29 | Raymond James Financial | Upgrade | Market Perform -> Outperform |
| 2021-04-14 | Raymond James Financial | Reiterate | Market Perform |
| 2021-04-05 | ATB Capital | Downgrade | Speculative Buy |
| 2021-03-04 | Raymond James Financial | Initiate | Market Perform |
8 analysts have analysed CRDL.CA and the average price target is 9.95 CAD. This implies a price increase of 576.53% is expected in the next year compared to the current price of 1.47.
The consensus rating for CARDIOL THERAPEUTICS INC-A (CRDL.CA) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering CARDIOL THERAPEUTICS INC-A (CRDL.CA) is 8.